Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CAB Payments gross income falls in 'reset year'

(Sharecast News) - Cross-border payments specialist CAB Payments said on Thursday that gross income had fallen in what it called a "reset year". CAB Payments said gross income fell 23% to £105.5m, predominantly due to exceptional Nigerian Naira, Central African Franc and West African Franc business in 2023.

Wholesale FX and payments gross income was down 39% at £53.8m, while NXX income reduced by £31.4m year-on-year.

CAB also noted that a stronger USD lowered average transaction values and suppressed volume growth and take-rates in emerging markets. In developed markets, a higher mix of G10 currency trading reduced the overall blended take-rate.

On the other hand, active client numbers and volumes both grew 7%, and the group generated £16.m in adjusted profits after tax for FY24, in line with market expectations.

Chief executive Neeraj Kapur said: "We have made solid strategic progress in our transformation.

"2024 was a 'reset' year. Since then our new and highly experienced senior leadership team is now in place and executing well against our plans driving deeper, stronger and trusted relationships with our clients, central banks and counterparties.

As of 1055 GMT, CAB Payments shares were down 5.60% at 50.60p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.